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posensit ization when given over a 1- or 3-week schedule. Larger 
booster doses after ini t ial desensitization appeared not to affect 
immunosuppression when given to animals desensitized on a 
high-dose schedule. However, large booster doses given to ani-
mals desensitized using a low-dose schedule produced a prom-
inent rebound in sensitivity. These findings indicate that clinical 
studies to determine the optimal dose a nd dosage schedule in 
humans will be needed. 
Relatively large oral doses (100 mg/kg; or approximately 50 
mg/animal) were required to produce hyposensitization, while 
in previous studies (7] intravenous doses of 6 mg PIU:POU 
acetate mixture (1:1) produced hyposensitization and 16 mg 
desensitized 54% of treated animals to 3.2-J.tg doses of PDC. The 
remaining animals were markedly hyposensitized. These find-
ings are in agreement with clinical findings in humans showing 
t hat smaller cumulative doses of oleoresin are required for 
maximal hyposensit ization via t he parenteral route as compar ed 
to the oral route [1]. The requirement of larger oral as compared 
to parenteral doses to produce substantial hyposensit ization is 
probably due to poor gastroin testinal a bsorption of umshiols 
fro m corn oil solutions (12]. The pattern of hyposensitization 
observed in our a nimal studies resembles that seen in humans; 
namely, hyposensitization is first noticed by a decrease in 
sensitivity to the highest dilutions. With time and continued 
administration of allergen the hyposensitization develops to the 
stronger concentrations until the a nin1als are maximally hypo-
sensit ized or desensit ized. The data in Table III illustrate this 
pattern most effectively. 
The waning of hyposensitization with time that often occurs 
in huma ns after cessation of dosing has not been observed in 
our animal studies. However, long-term follow-up studies in 
guinea pigs are hampered by the .gradual natura l decrease in 
sensitivity of the a nimals beginning 6 tc 8 weeks foll owing 
sensitization. For this same reason the benefi ts of maintenance 
doses of urushiol acetates in gu inea pigs cannot be easily 
determined. 
In addition to the superiori ty of esterified urushiol derivatives 
as desensitizing agents, comparative LD,,0 studies, local tissue 
reactions, and skin irri tation studies (data to be published 
elsewhere) showed that the esterified urushiols are substantially 
less toxic than their unclerivatizecl counterparts. The fact that 
the esterified urushiols a re more effective desensitizers and less 
tox ic points to a better therapeutic index for the urushiol esters. 
There have been clinical reports attempting to associate 
desensitization therapy with renal toxicity [13]. However, a 
chronic 6-month study in rats closed orally with free and ester-
ified urushiols (data to be published elsewhere) showed no renal 
tox icity with either form. Additionally, we have not observed 
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a ny tox ic effects from administration of the fTee or esterified 
urushiol in guinea pigs. Moreover, we have not been able to 
elicit peria nal dermatitis in guinea pigs even when 3-J.tg test 
doses of mushiol are applied directly to the anus. However, the 
guinea pig and rat may not be ideal animals in which to study 
the systemic toxic effects of urushiols since gastrointestinal 
irri tation a nd perianal dermatitis have been observed in humans 
after administration of free urushiols. 
The authors wish to tha nk Paula Whatley and Dr. Paul Skierkowski 
for assistance in the preparat ion of this manuscript.. 
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The Harvard Medical School Department of Continuing Education and the Laser Uni t of the Beth Israel Hospi~al , 
Boston, are sponsoring a one-day course entitled "Cutaneous Laser Surgery" to be held at t he Beth Isr~el Hospital 
on September 24, 1983. For further information: Kenneth A. Arndt, M.D., Beth Israel Hospital, 330 Brooklme Avenue, 
Boston Massachusetts 0?.215. 
"Learning Clinical Dermatology Through Dermatopathology," a Symposium presented by Departments of 
Dermatology a nd Pathology of New York University School of M.edicine, will ?e h eld at that_Dniversity ?ctober 6-8, 
1983. For informatio n: A. Bernard Ackerman, M.D. New York Umversity Medical Center, S UJ te 71, 530 F irst Avenue, 
N ew York, New York 10016. 
